Lytix Biopharma: Q4 2025 Presentation and Publication of H2 2025 Interim Report
12 februari, 07:05
Lytix Biopharma: Q4 2025 Presentation and Publication of H2 2025 Interim Report
Oslo, Norway, February 12, 2026 – Lytix Biopharma AS (“Lytix” or the “Company”) today published its interim financial report for the second half of 2025 and released its fourth quarter 2025 presentation.
The interim report has been prepared in accordance with IAS 34 and includes financial information for the fourth quarter and the second half of 2025.
Q4 2025 highlights and developments
- Positive interim clinical data from the Phase II NeoLIPA neoadjuvant melanoma study were presented by Dr Henrik Jespersen at the Nordic Melanoma Meeting in November 2025. Overall pathological responses was obtained in nearly 90% of patients treated with ruxotemitide in combination with pembrolizumab.
- Licensing partner Verrica Pharmaceuticals presented new immune-response data from its ongoing Phase II study with ruxotemitide in basal cell carcinoma at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting.
- The ATLAS-IT-05 Phase II study in advanced melanoma was completed, with preparation of the clinical study report ongoing and expected to be finalized in the first quarter of 2026.
- Evaluating all strategic opportunities to accelerate the development of LTX-401.
- Cash and short-term financial investments totaled NOK 72.4 million at year-end 2025, reflecting disciplined cost management and reduced operating loss following completion of major clinical activities.
Ruxotemitide is progressing toward commercialization via multiple avenues: our internal work on neoadjuvant melanoma via the NeoLIPA study and our internal planning towards a pivotal study; Active partnering conversations to ensure strategic optionality; and Verica Pharmaceuticals continued efforts to source non-dilutive funding for a pivotal trial in basal cell carcinoma. These initiatives offer multiple opportunities to create significant market value in superficial tumors.
Lytix remains open to valuable partnerships that can speed up development, maximize the global potential of the program, and ensure patients gain access to this drug as quickly as possible. With continued financial discipline, Lytix remains well-positioned for 2026.
Comment from management
“The data presented during the quarter at the Nordic Melanoma Meeting and at the Society for Immunotherapy of Cancer underscore the consistency and breadth of ruxotemitide’s immune-mediated activity across disease settings,” said Øystein Rekdal, CEO of Lytix Biopharma. “Seeing strong pathological responses in early-stage melanoma alongside immune activation data in basal cell carcinoma is deeply motivating for the entire team and represents an important milestone as we advance ruxotemitide toward the next phase of development.”
The Company’s fourth quarter 2025 results and developments will be presented in a live webcast with CEO Øystein Rekdal and CFO Gjest Breistein today at 10:00 CET.
Webcast details:
Date: Thursday, February 12, 2026
Time: 10:00 CET
Questions may be submitted in advance to: post@lytixbiopharma.com
The presentation and subsequent Q&A session will be conducted in English and can be viewed live by registering here:
https://qcnl.tv/p/Bs5cUOyZOtu__8Vd3OK5_Q
A recording of the presentation will be made available after the webcast at:
https://www.lytixbiopharma.com/financial-reports
The interim report for the second half of 2025 and the fourth quarter presentation are available on the Company’s website.
For further information, please contact:
Gjest Breistein, CFO
+47 952 60 512
gjest.breistein@lytixbiopharma.com
About Lytix
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with a highly differentiated oncolytic molecule platform based on world-leading research in host-defense peptide-derived molecules. Lytix Biopharma’s lead product, ruxotemitide (formerly LTX-315), is a first-in-class oncolytic molecule representing a new approach to maintaining durable anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that work across multiple cancer indications and treatment settings, both as mono- and combination therapy. Lytix is listed on Euronext Growth Oslo under the ticker LYTIX.
For more information, visit www.lytixbiopharma.com
Ämnen i artikeln
Lytix Biopharma: Q4 2025 Presentation and Publication of H2 2025 Interim Report
12 februari, 07:05
Lytix Biopharma: Q4 2025 Presentation and Publication of H2 2025 Interim Report
Oslo, Norway, February 12, 2026 – Lytix Biopharma AS (“Lytix” or the “Company”) today published its interim financial report for the second half of 2025 and released its fourth quarter 2025 presentation.
The interim report has been prepared in accordance with IAS 34 and includes financial information for the fourth quarter and the second half of 2025.
Q4 2025 highlights and developments
- Positive interim clinical data from the Phase II NeoLIPA neoadjuvant melanoma study were presented by Dr Henrik Jespersen at the Nordic Melanoma Meeting in November 2025. Overall pathological responses was obtained in nearly 90% of patients treated with ruxotemitide in combination with pembrolizumab.
- Licensing partner Verrica Pharmaceuticals presented new immune-response data from its ongoing Phase II study with ruxotemitide in basal cell carcinoma at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting.
- The ATLAS-IT-05 Phase II study in advanced melanoma was completed, with preparation of the clinical study report ongoing and expected to be finalized in the first quarter of 2026.
- Evaluating all strategic opportunities to accelerate the development of LTX-401.
- Cash and short-term financial investments totaled NOK 72.4 million at year-end 2025, reflecting disciplined cost management and reduced operating loss following completion of major clinical activities.
Ruxotemitide is progressing toward commercialization via multiple avenues: our internal work on neoadjuvant melanoma via the NeoLIPA study and our internal planning towards a pivotal study; Active partnering conversations to ensure strategic optionality; and Verica Pharmaceuticals continued efforts to source non-dilutive funding for a pivotal trial in basal cell carcinoma. These initiatives offer multiple opportunities to create significant market value in superficial tumors.
Lytix remains open to valuable partnerships that can speed up development, maximize the global potential of the program, and ensure patients gain access to this drug as quickly as possible. With continued financial discipline, Lytix remains well-positioned for 2026.
Comment from management
“The data presented during the quarter at the Nordic Melanoma Meeting and at the Society for Immunotherapy of Cancer underscore the consistency and breadth of ruxotemitide’s immune-mediated activity across disease settings,” said Øystein Rekdal, CEO of Lytix Biopharma. “Seeing strong pathological responses in early-stage melanoma alongside immune activation data in basal cell carcinoma is deeply motivating for the entire team and represents an important milestone as we advance ruxotemitide toward the next phase of development.”
The Company’s fourth quarter 2025 results and developments will be presented in a live webcast with CEO Øystein Rekdal and CFO Gjest Breistein today at 10:00 CET.
Webcast details:
Date: Thursday, February 12, 2026
Time: 10:00 CET
Questions may be submitted in advance to: post@lytixbiopharma.com
The presentation and subsequent Q&A session will be conducted in English and can be viewed live by registering here:
https://qcnl.tv/p/Bs5cUOyZOtu__8Vd3OK5_Q
A recording of the presentation will be made available after the webcast at:
https://www.lytixbiopharma.com/financial-reports
The interim report for the second half of 2025 and the fourth quarter presentation are available on the Company’s website.
For further information, please contact:
Gjest Breistein, CFO
+47 952 60 512
gjest.breistein@lytixbiopharma.com
About Lytix
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with a highly differentiated oncolytic molecule platform based on world-leading research in host-defense peptide-derived molecules. Lytix Biopharma’s lead product, ruxotemitide (formerly LTX-315), is a first-in-class oncolytic molecule representing a new approach to maintaining durable anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that work across multiple cancer indications and treatment settings, both as mono- and combination therapy. Lytix is listed on Euronext Growth Oslo under the ticker LYTIX.
For more information, visit www.lytixbiopharma.com
Ämnen i artikeln
Familjen Rausing i EQT
Analyser
Familjen Rausing i EQT
Analyser
Marknadsöversikt
1 DAG %
Senast
1 mån
